AP2014008137A0 - Camsylate salt - Google Patents

Camsylate salt

Info

Publication number
AP2014008137A0
AP2014008137A0 AP2014008137A AP2014008137A AP2014008137A0 AP 2014008137 A0 AP2014008137 A0 AP 2014008137A0 AP 2014008137 A AP2014008137 A AP 2014008137A AP 2014008137 A AP2014008137 A AP 2014008137A AP 2014008137 A0 AP2014008137 A0 AP 2014008137A0
Authority
AP
ARIPO
Prior art keywords
camsylate salt
camsylate
salt
Prior art date
Application number
AP2014008137A
Other languages
English (en)
Inventor
Craig Robert Stewart
Martin Hans Bohlin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AP2014008137A0 publication Critical patent/AP2014008137A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AP2014008137A 2012-06-21 2013-06-20 Camsylate salt AP2014008137A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261662592P 2012-06-21 2012-06-21
PCT/GB2013/051606 WO2013190302A1 (en) 2012-06-21 2013-06-20 Camsylate salt

Publications (1)

Publication Number Publication Date
AP2014008137A0 true AP2014008137A0 (en) 2014-12-31

Family

ID=48746084

Family Applications (2)

Application Number Title Priority Date Filing Date
AP2014008137A AP2014008137A0 (en) 2012-06-21 2013-06-20 Camsylate salt
AP2017009693A AP2017009693A0 (en) 2012-06-21 2013-06-20 Camsylate salt

Family Applications After (1)

Application Number Title Priority Date Filing Date
AP2017009693A AP2017009693A0 (en) 2012-06-21 2013-06-20 Camsylate salt

Country Status (42)

Country Link
US (1) US10548882B2 (enExample)
EP (2) EP3064494A1 (enExample)
JP (2) JP2015520221A (enExample)
KR (1) KR102123708B1 (enExample)
CN (2) CN106279102A (enExample)
AP (2) AP2014008137A0 (enExample)
AR (2) AR091495A1 (enExample)
AU (2) AU2013279109B2 (enExample)
BR (2) BR122016014302B1 (enExample)
CA (1) CA2875589C (enExample)
CL (1) CL2014003374A1 (enExample)
CO (1) CO7151486A2 (enExample)
CR (2) CR20140571A (enExample)
CY (1) CY1119505T1 (enExample)
DK (1) DK2864316T3 (enExample)
DO (1) DOP2014000268A (enExample)
EC (1) ECSP14032215A (enExample)
ES (1) ES2618939T3 (enExample)
HR (1) HRP20170359T1 (enExample)
HU (1) HUE033376T2 (enExample)
IL (1) IL236131A0 (enExample)
IN (1) IN2014DN10088A (enExample)
LT (1) LT2864316T (enExample)
MA (2) MA39259B1 (enExample)
ME (1) ME02633B (enExample)
MX (1) MX354214B (enExample)
NI (1) NI201400146A (enExample)
NZ (2) NZ702742A (enExample)
PE (1) PE20150670A1 (enExample)
PH (2) PH12014502803B1 (enExample)
PL (1) PL2864316T3 (enExample)
PT (1) PT2864316T (enExample)
RS (1) RS55815B1 (enExample)
RU (1) RU2638175C2 (enExample)
SG (1) SG11201407934UA (enExample)
SI (1) SI2864316T1 (enExample)
SM (1) SMT201700142T1 (enExample)
TN (1) TN2014000491A1 (enExample)
TW (2) TWI588140B (enExample)
UA (1) UA114196C2 (enExample)
WO (1) WO2013190302A1 (enExample)
ZA (1) ZA201500408B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
ES2566373T3 (es) 2011-10-10 2016-04-12 Astrazeneca Ab Inhibidores monofluoro beta-secretasa
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US10053453B2 (en) 2014-10-07 2018-08-21 Astrazeneca Ab Compounds and their use as BACE inhibitors
JP6546410B2 (ja) * 2015-02-23 2019-07-17 ローム株式会社 電力供給装置、acアダプタ、acチャージャ、電子機器および電力供給システム
AR107893A1 (es) * 2016-03-15 2018-06-28 Astrazeneca Ab TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE
TW201740944A (zh) 2016-03-15 2017-12-01 美國禮來大藥廠 組合療法
MX2021011105A (es) * 2019-03-14 2021-10-22 Astrazeneca Ab Lanabecestat para la perdida de peso.

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100452491B1 (ko) * 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
JP4273406B2 (ja) 2001-06-01 2009-06-03 小野薬品工業株式会社 アルドース還元酵素阻害剤を有効成分とする脱髄性疾患または脱髄を伴う疾患治療剤
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
ES2332184T3 (es) 2004-03-22 2010-01-28 ELI LILLY & COMPANY Derivados de piridilo y su uso como antagonistas del receptor mglu5.
WO2006138264A2 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
CN101360716A (zh) 2005-11-21 2009-02-04 阿斯利康(瑞典)有限公司 新颖的2-氨基-咪唑-4-酮化合物及其在制备用于治疗认知缺损、阿尔茨海默病、神经变性和痴呆的药物中的用途
JP2009521488A (ja) 2005-12-21 2009-06-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pkc−シータのインヒビターとして有益なピリミジン誘導体
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
CA2653650A1 (en) 2006-06-12 2007-12-21 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2008076043A1 (en) 2006-12-20 2008-06-26 Astrazeneca Ab Novel 2-amino-5,5-diaryl-imidazol-4-ones
US20090325993A1 (en) 2007-02-01 2009-12-31 Nadia Mamoona Ahmad GLYT1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders
MX2009012177A (es) 2007-05-07 2009-11-23 Schering Corp Moduladores de gamma-secretasa.
EP2249646A4 (en) 2008-02-06 2013-09-25 Glaxo Group Ltd PDE4 muscarinic Antagonist-DOPPELPHARMACOPHOREN
FR2929943B1 (fr) * 2008-04-15 2010-09-24 Inst Rech Developpement Ird Sels de quinoleines 2-substituees
AU2009277485B2 (en) 2008-07-28 2013-05-02 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
US8450308B2 (en) 2008-08-19 2013-05-28 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
MX2011002705A (es) 2008-09-11 2011-09-09 Amgen Inc Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso.
WO2010105179A2 (en) 2009-03-13 2010-09-16 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
UY32751A (es) 2009-07-02 2011-01-31 Astrazeneca Ab Imidazoles sustituidos y uso de los mismos
UY32750A (es) 2009-07-02 2011-01-31 Astrazeneca Ab Imidazoles sustituidos y uso de los mismos
JP5828848B2 (ja) 2010-02-24 2015-12-09 ヴァイティー ファーマシューティカルズ,インコーポレイテッド ベータセクレターゼインヒビター
WO2011123674A1 (en) 2010-03-31 2011-10-06 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
WO2011130741A1 (en) 2010-04-16 2011-10-20 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
WO2012019056A1 (en) 2010-08-05 2012-02-09 Amgen Inc. Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use
US20120083501A1 (en) 2010-09-24 2012-04-05 Hunt Kevin W Compounds for treating neurodegenerative diseases
US20120157448A1 (en) 2010-11-22 2012-06-21 Adam Cook Compounds for treating neurodegenerative diseases
US8415483B2 (en) * 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
ES2566373T3 (es) 2011-10-10 2016-04-12 Astrazeneca Ab Inhibidores monofluoro beta-secretasa
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors

Also Published As

Publication number Publication date
KR20150023388A (ko) 2015-03-05
PH12014502803A1 (en) 2015-02-23
SG11201407934UA (en) 2015-01-29
ZA201500408B (en) 2016-10-26
AU2017254965B2 (en) 2019-05-09
JP2015520221A (ja) 2015-07-16
JP2018104448A (ja) 2018-07-05
MX354214B (es) 2018-02-19
CR20140571A (es) 2015-02-04
EP3064494A1 (en) 2016-09-07
CO7151486A2 (es) 2014-12-29
HK1206349A1 (en) 2016-01-08
IL236131A0 (en) 2015-02-01
TN2014000491A1 (en) 2016-03-30
AU2017254965A1 (en) 2017-11-23
BR112014031531A2 (pt) 2017-06-27
CY1119505T1 (el) 2018-03-07
SMT201700142T1 (it) 2017-05-08
AU2013279109A1 (en) 2015-01-15
CA2875589A1 (en) 2013-12-27
NZ702742A (en) 2016-12-23
MA39259B1 (fr) 2018-09-28
LT2864316T (lt) 2017-03-27
DOP2014000268A (es) 2015-04-15
US10548882B2 (en) 2020-02-04
US20140031379A1 (en) 2014-01-30
RU2638175C2 (ru) 2017-12-12
PH12016500498A1 (en) 2017-04-10
MA37666B1 (fr) 2016-12-30
TW201730177A (zh) 2017-09-01
RS55815B1 (sr) 2017-08-31
RU2014148305A (ru) 2016-08-10
CL2014003374A1 (es) 2015-02-27
TWI639591B (zh) 2018-11-01
EP2864316B1 (en) 2016-12-14
ECSP14032215A (es) 2015-12-31
CR20160202A (es) 2016-07-26
PE20150670A1 (es) 2015-06-03
CN104411697A (zh) 2015-03-11
NI201400146A (es) 2016-09-21
DK2864316T3 (en) 2017-03-20
BR122016014302A2 (pt) 2019-08-27
BR112014031531B1 (pt) 2022-08-02
AP2017009693A0 (en) 2017-01-31
PT2864316T (pt) 2017-02-24
TW201406745A (zh) 2014-02-16
ME02633B (me) 2017-06-20
EP2864316A1 (en) 2015-04-29
ES2618939T3 (es) 2017-06-22
AR105176A2 (es) 2017-09-13
JP6509393B2 (ja) 2019-05-08
PL2864316T3 (pl) 2017-09-29
PH12014502803B1 (en) 2015-02-23
MA39259A1 (fr) 2017-12-29
HUE033376T2 (en) 2017-11-28
KR102123708B1 (ko) 2020-06-16
TWI588140B (zh) 2017-06-21
AU2013279109B2 (en) 2017-08-31
WO2013190302A1 (en) 2013-12-27
BR122016014302B1 (pt) 2022-08-23
MX2014014709A (es) 2015-03-04
CA2875589C (en) 2020-08-25
SI2864316T1 (sl) 2017-04-26
IN2014DN10088A (enExample) 2015-08-21
HRP20170359T1 (hr) 2017-05-05
CN104411697B (zh) 2016-08-10
UA114196C2 (uk) 2017-05-10
MA37666A1 (fr) 2016-04-29
NZ727045A (en) 2018-06-29
CN106279102A (zh) 2017-01-04
AR091495A1 (es) 2015-02-11

Similar Documents

Publication Publication Date Title
IL268013A (en) Tetrahydropyrazolopyrimidine compounds
ZA201407694B (en) Substituted pyrrolidine-2-carboxamides
IL237341A0 (en) Compounds that promote neurogenesis
AP2014007810A0 (en) Imidazopyrrolidinone compounds
GB201209138D0 (en) Compounds
SG11201404344XA (en) Substituted pyrrolidine-2-carboxamides
GB201215357D0 (en) Compounds
GB201214750D0 (en) Compounds
EP2934541A4 (en) SUBSTITUTED NORIBOGAIN
EP2828262A4 (en) IMIDAZOTRIAZINONVERBINDUNGEN
GB201204985D0 (en) Compounds
ZA201500408B (en) Camsylate salt
GB201204125D0 (en) Compounds
SI2836495T1 (sl) Spojine tetrahidropirolotiazina
GB201209096D0 (en) Compounds
PL2840907T3 (pl) Substytut soli
GB201219820D0 (en) Compounds
IL239281A0 (en) Dihydrochloride salt of cubicistat
GB201217310D0 (en) Compounds
PL2760822T3 (pl) Sole desfezoterodyny
GB201223429D0 (en) Compounds
GB201220029D0 (en) Compounds
GB201219819D0 (en) Compounds
GB201218799D0 (en) Compounds
GB201218776D0 (en) Compounds